Srx MedicinePub Date : 2010-03-30DOI: 10.3814/2010/581923
L. Margolin, A. Monselise
{"title":"Fatal Mimicry: Oral Melanoma versus Mantle Cell Lymphoma","authors":"L. Margolin, A. Monselise","doi":"10.3814/2010/581923","DOIUrl":"https://doi.org/10.3814/2010/581923","url":null,"abstract":"We present a 71-year-old male with oral melanoma and mantle cell hyperplasia who was erroneously diagnosed and treated as mantle cell lymphoma. The differential diagnosis of MCL versus mantle cell hyperplasia is a challenging task. Thorough immunohistochemical and cytogenetic analyses are warranted before treatment administration. The more common presentation of amelanotic malignant melanoma requires a high index of suspicion for masses identified in the mouth and requires biopsy for definitive diagnosis. A meticulous physical examination is advocated.","PeriodicalId":438743,"journal":{"name":"Srx Medicine","volume":"2010 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130688123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Srx MedicinePub Date : 2010-02-21DOI: 10.3814/2010/812304
L. Porrata, S. Markovic
{"title":"Is Absolute Lymphocyte Count Just Another Prognostic Factor in Cancer","authors":"L. Porrata, S. Markovic","doi":"10.3814/2010/812304","DOIUrl":"https://doi.org/10.3814/2010/812304","url":null,"abstract":"The role of host immunity in cancer clinical outcomes has been wellestablished in animal models. In humans, the impact of the immune system as a therapeutic maneuver to treat malignancies has been proven by the development of graft-versus-tumor effect observed in the allogeneic stem cell transplantation. However, with few notable exceptions, no definitive conclusions have been reached as to the role of host immunity in humans and its impact on cancer outcomes. This article reviews the clinical evidence of how human immunity can affect cancer clinical outcomes using the absolute lymphocyte count as a surrogate maker of host immune competence.","PeriodicalId":438743,"journal":{"name":"Srx Medicine","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128239123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Srx MedicinePub Date : 2010-01-13DOI: 10.3814/2010/973413
K. Takebayashi, M. Suetsugu, Y. Aso, T. Inukai
{"title":"Long-Term Effect of Colestimide on Glycemic Control in Patients with Type 2 Diabetes with Elevated Low-Density Lipoprotein Cholesterol Levels","authors":"K. Takebayashi, M. Suetsugu, Y. Aso, T. Inukai","doi":"10.3814/2010/973413","DOIUrl":"https://doi.org/10.3814/2010/973413","url":null,"abstract":"Objective. Bile acid sequestrants (BASs) have been shown to improve both low-density lipoprotein-(LDL-) cholesterol and hemoglobin (Hb) A1c levels in patients with type 2 diabetes with elevated LDL levels. However, the longitudinal effect on glycemic control in these patients has not been fully examined. In the current study, the effect of colestimide (a BAS used in Japan, called also as colestilan) over a mean period of 18 months was investigated in patients with type 2 diabetes with elevated LDL levels. \u0000Methods. The study was performed prospectively in 34 patients with type 2 diabetes with elevated LDL levels who started colestimide (3.0 g a day) between April 2007 and March 2008. \u0000Results. HbA1c was significantly decreased after 3 months of colestimide therapy and at the end point of treatment (a mean period of 18 months) compared with baseline values (8.1%±1.1% at baseline, 7.1%±0.7% at 3 months, and 7.2%±0.9% at the end point; both P .05, 3 months versus end point). Colestimide also significantly reduced LDL-C at 3 months and at the end point (both P .05, 3 months versus end point). However, fasting plasma glucose, triglycerides, systolic and diastolic blood pressure, and body weight did not differ significantly after 3 months and at the end point compared with the respective baseline values. \u0000Conclusion. Colestimide significantly decreased HbA1c over a relatively long-term period in patients with type 2 diabetes with elevated LDL levels.","PeriodicalId":438743,"journal":{"name":"Srx Medicine","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134340172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Srx MedicinePub Date : 2010-01-13DOI: 10.3814/2010/326840
K. Takebayashi, Rika Naruse, Y. Aso, T. Inukai
{"title":"The Effect of Amlodipine on Oxidative Stress in Patients with Type 2 Diabetes","authors":"K. Takebayashi, Rika Naruse, Y. Aso, T. Inukai","doi":"10.3814/2010/326840","DOIUrl":"https://doi.org/10.3814/2010/326840","url":null,"abstract":"Background. Amlodipine, a calcium channel blocker, is reported to have an antioxidative effect in vitro, but whether such an effect occurs clinically is unknown. The purpose of the study was to investigate the effect of amlodipine (5 mg/day) on oxidative stress by measuring urinary 8-iso-prostaglandin F2α (8-iso-PGF2α), an oxidative stress marker, in patients with type 2 diabetes. The anti-oxidative effect of amlodipine was also assessed using the levels of high-sensitivity C-reactive protein (hsCRP) and fibrinogen. Patients and Methods. Seventeen consecutive patients with type 2 diabetes complicated by hypertension were prospectively enrolled in the study. These patients received amlodipine (5 mg/day) over a 3-month period and various markers were measured before and at the end of this period. Results. Urinary 8-iso-PGF2α showed a tendency to decrease, but the change was not statistically significant (P=.1127). The patients were divided into two groups according to the baseline level of urinary 8-iso-PGF2α, and a significant decrease in 8-iso-PGF2α was found in the group (n=9) with a relatively high baseline 8-iso-PGF2α. There were no changes in hsCRP, fibrinogen, and plasminogen activator inhibitor-1. Significant decreases in systolic and diastolic blood pressure were observed (P<.0001, P=.0151, resp.). Conclusion. The results show that amlodipine (5 mg/day) may provide a clinically useful anti-oxidative effect, based on evaluation of urinary 8-iso-PGF2α.","PeriodicalId":438743,"journal":{"name":"Srx Medicine","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132798708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Srx MedicinePub Date : 1900-01-01DOI: 10.3814/2010/975915
N. Morelli, M. Mancuso, C. Tavarelli, S. Gallerini, G. Cafforio, S. Delucchi, D. Guidetti
{"title":"Giant Schwannoma with Endoabdominal Development: A Case of Radiculopathy","authors":"N. Morelli, M. Mancuso, C. Tavarelli, S. Gallerini, G. Cafforio, S. Delucchi, D. Guidetti","doi":"10.3814/2010/975915","DOIUrl":"https://doi.org/10.3814/2010/975915","url":null,"abstract":"Lumbosacral radiculopathy is a very common pathology, frequently caused by degenerative spondyloarthropathies. However, radiculopathy may result from tumor in various locations within the spinal canal, more commonly extramedullary. Primary nerve root tumors are a rare cause of lumbosacral radiculopathy. The majority of primary spinal tumors are benign and slow growing, and their clinical manifestations may be difficult to distinguish from more common causes of radiculopathy, such as a disc herniation. To our knowledge, voluminous schwannomas with endoabdominal development have only rarely been observed. Lumbosacral radiculopathy is a common neurological syndrome which can be an important source of disability. Although the most common causes are disc herniation and chronic spinal arthropathy, physicians should be mindful of other causes, including neoplasms.","PeriodicalId":438743,"journal":{"name":"Srx Medicine","volume":"195 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121245551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}